Results 281 to 290 of about 1,490,578 (344)

Emerging Challenges and Advances in Porcine Circovirus: A Decade in Review. [PDF]

Transbound Emerg Dis
Zheng J, Zhang G, Li P, Ren L.
europepmc   +1 more source

Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza. [PDF]

Nat Commun
Ykema MR, Davis MA, Kasal DN, Jennewein MF, Lo E, Singh J, Beaver S, Cross N, Melief E, Reed S, Press C, Brandt DS, McClary WD, Mohamath R, Fusco P, Bakken J, Casper C, Hartwig AT, Gerhardt A, Bowen RA, Voigt EA.   +20 more
europepmc   +1 more source

Next-Generation Vaccines for Co-Circulating PEDV and TGEV: Integrating Nucleic Acid Platforms, Mucosal Delivery, and AI-Driven Antigen Design. [PDF]

Transbound Emerg Dis
Hu X, Wang Z, Wang S, Sun H, Feng N, Li E, Xia X, Hu G, Yan F, Li B.   +9 more
europepmc   +1 more source

Reviewer #2 (Public Review): Purging viral latency by a bifunctional HSV-vectored therapeutic vaccine in chronically SIV-infected macaques

Ziyu Wen, Pingchao Li, Yue Yuan, Congcong Wang, Minchao Li, Haohang Wang, Minjuan Shi, Yizi He, Mingting Cui, Ling Chen, Caijun Sun   +10 more
openalex   +1 more source

Miscellaneous viral vaccines.

Indian journal of medical sciences, 1969
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Viral Vector Vaccines

VacciTUTOR, 2021
Viral vector vaccines use harmless, non-replicating or replicating viruses to deliver genetic material for production of vaccine antigens into host cell cytoplasm. While viral vector vaccines may theoretically induce life-long immunity with low antigen concentrations, their attenuation, safety and spread to the community are of concern. Vaccines based
Valerie Oriol Mathieu, Mark van Ooij, Kerstin Lühn, Jeff Stoddard   +3 more
openaire   +2 more sources

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.

Journal of the American Medical Association (JAMA), 2021
and B.1.1.7 variants, and those sequence changes are more worrisome because they are located in or close to the RBD; these sequence changes also affect another NAb target, the N-terminal domain.
John P. Moore, P. Offit
semanticscholar   +1 more source

Viral Hepatitis Vaccines

Annual Review of Medicine, 1985
Purified from the plasma of hepatitis B carriers, hepatitis B surface antigen particles have been used in a vaccine to prevent hepatitis B. This plasma-derived vaccine is immunogenic, protective, and has an excellent safety record. Indications and strategies for preexposure and postexposure prophylaxis are reviewed.
I M, Jacobson, J L, Dienstag
openaire   +3 more sources

Synthetic Viral Vaccines

Annual Review of Microbiology, 1984
INTRODUCTION...... ..... 221 Vaccines in the Control of Virus Diseases .....
openaire   +2 more sources